NDAORALCAPSULE
Approved
Apr 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
SOMA (carisoprodol) by Viatris (2) is identified. First approved in 1959.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMA (carisoprodol) is an oral muscle relaxant approved in 1959 for acute musculoskeletal pain and stiffness. It works by altering interneuronal activity in the spinal cord and descending reticular formation of the brain to reduce muscle tension. Carisoprodol is a small-molecule centrally acting agent indicated for short-term adjunctive therapy.
$0.002BPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal recent spending, indicating reduced team size and commercial investment focus.
Mechanism of Action
identified. In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.
Pharmacologic Class:
Muscle Relaxant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Started Aug 2026
136 enrolled
VEXAS Syndrome
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Started Aug 2026
80 enrolled
Duchenne Muscular Dystrophy (DMD)
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Started Jul 2026
84 enrolled
Turner Syndrome
A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
Started Jul 2026
28 enrolled
Autosomal Dominant RYR1-Related Myopathy
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Started Jul 2026
428 enrolled
Talaromycosis
Worked on SOMA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.